 |
 |

HEALTH CARE REFORM
Clinicians' Assessments of Electronic Medication Safety Alerts in Ambulatory Care
Saul N. Weingart, MD, PhD;
Brett Simchowitz, BA;
Lawrence Shiman, MPP;
Daniela Brouillard, BA;
Adrienne Cyrulik, MPH;
Roger B. Davis, ScD;
Thomas Isaac, MD, MPH, MBA;
Michael Massagli, PhD;
Laurinda Morway, MEd;
Daniel Z. Sands, MD, MPH;
Justin Spencer, MPA;
Joel S. Weissman, PhD
Arch Intern Med. 2009;169(17):1627-1632.
Background While electronic prescribing (e-prescribing) systems with drug interaction and allergy alerts promise to improve medication safety in ambulatory care, clinicians often override these safety features. We undertook a study of respondents' satisfaction with e-prescribing systems, their perceptions of alerts, and their perceptions of behavior changes resulting from alerts.
Methods Random sample survey of 300 Massachusetts ambulatory care clinicians who used a commercial e-prescribing system.
Results A total of 184 respondents completed the survey (61%). Respondents indicated that e-prescribing improved the quality of care delivered (78%), prevented medical errors (83%), and enhanced patient satisfaction (71%) and clinician efficiency (75%). In addition, 35% of prescribers said that electronic alerts caused them to modify a potentially dangerous prescription in the last 30 days. They suggested that alerts also led to other changes in clinical care: counseling patients about potential reactions (49% of respondents), looking up information in medical references (44%), and changing the way a patient was monitored (33%). Altogether, 63% of clinicians reported taking action other than discontinuing or modifying an alerted prescription in the previous month in response to alerts. Despite these benefits, fewer than half of respondents were satisfied with drug interaction and allergy alerts (47%). Problems included alerts triggered by discontinued medications (58%), alerts that failed to account for appropriate drug combinations (46%), and excessive volume of alerts (37%).
Conclusion Although clinicians were critical of the quality of e-prescribing alerts, alerts may lead to clinically significant modifications in patient management not readily apparent based on "acceptance" rates.
Author Affiliations: Center for Patient Safety, Dana-Farber Cancer Institute, Boston, Massachusetts (Drs Weingart and Isaac, Messrs Simchowitz, Shiman, and Spencer, and Mss Brouillard and Morway); Harvard Medical School, Boston (Drs Weingart, Davis, Isaac, Sands, and Weissman); Blue Cross Blue Shield of Massachusetts, Boston (Ms Cyrulik); Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston (Drs Davis, Isaac, and Sands); PatientsLikeMe, Cambridge, Massachusetts (Dr Massagli); Cisco, San Jose, California (Dr Sands); Institute for Health Policy, Massachusetts General Hospital, Boston (Dr Weissman); Executive Office of Health and Human Services, Commonwealth of Massachusetts, Boston (Dr Weissman); and University of Massachusetts Medical School, Worcester (Dr Weissman).
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Development and validation of a survey instrument for assessing prescribers' perception of computerized drug-drug interaction alerts
Zheng et al.
J Am Med Inform Assoc 2011;18:i51-i61.
ABSTRACT
| FULL TEXT
A clinical decision support needs assessment of community-based physicians
Richardson and Ash
J Am Med Inform Assoc 2011;18:i28-i35.
ABSTRACT
| FULL TEXT
Alternatives to potentially inappropriate medications for use in e-prescribing software: triggers and treatment algorithms
Hume et al.
BMJQS 2011;20:875-884.
ABSTRACT
| FULL TEXT
Critical issues associated with drug-drug interactions: Highlights of a multistakeholder conference
Hines et al.
Am J Health Syst Pharm 2011;68:941-946.
FULL TEXT
Differences Between Integrated And Stand-Alone E-Prescribing Systems Have Implications For Future Use
DesRoches et al.
Health Aff (Millwood) 2010;29:2268-2277.
ABSTRACT
| FULL TEXT
Randomized clinical trial of a customized electronic alert requiring an affirmative response compared to a control group receiving a commercial passive CPOE alert: NSAID-warfarin co-prescribing as a test case
Strom et al.
J Am Med Inform Assoc 2010;17:411-415.
ABSTRACT
| FULL TEXT
|